MX2020000406A - Tratamiento dirigido de la inestabilidad cromosómica y senalización del adn citosólico gen abajo para el tratamiento del cáncer. - Google Patents
Tratamiento dirigido de la inestabilidad cromosómica y senalización del adn citosólico gen abajo para el tratamiento del cáncer.Info
- Publication number
- MX2020000406A MX2020000406A MX2020000406A MX2020000406A MX2020000406A MX 2020000406 A MX2020000406 A MX 2020000406A MX 2020000406 A MX2020000406 A MX 2020000406A MX 2020000406 A MX2020000406 A MX 2020000406A MX 2020000406 A MX2020000406 A MX 2020000406A
- Authority
- MX
- Mexico
- Prior art keywords
- chromosomal
- cytosolic dna
- methods
- cancer treatment
- chromosomal instability
- Prior art date
Links
- 108020004414 DNA Proteins 0.000 title abstract 3
- 230000001086 cytosolic effect Effects 0.000 title abstract 3
- 208000037051 Chromosomal Instability Diseases 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- 230000011664 signaling Effects 0.000 title 1
- 230000008685 targeting Effects 0.000 title 1
- 230000002759 chromosomal effect Effects 0.000 abstract 4
- 238000000034 method Methods 0.000 abstract 4
- 239000000203 mixture Substances 0.000 abstract 3
- 208000037819 metastatic cancer Diseases 0.000 abstract 2
- 208000011575 metastatic malignant neoplasm Diseases 0.000 abstract 2
- 102100031256 Cyclic GMP-AMP synthase Human genes 0.000 abstract 1
- 101710118064 Cyclic GMP-AMP synthase Proteins 0.000 abstract 1
- 101001006793 Dictyostelium discoideum Kinesin-related protein 6 Proteins 0.000 abstract 1
- 101001091266 Homo sapiens Kinesin-like protein KIF13A Proteins 0.000 abstract 1
- 101000812677 Homo sapiens Nucleotide pyrophosphatase Proteins 0.000 abstract 1
- 101150036156 KIF2B gene Proteins 0.000 abstract 1
- 101150063084 KIF2C gene Proteins 0.000 abstract 1
- 102100034865 Kinesin-like protein KIF13A Human genes 0.000 abstract 1
- 101710134369 Kinesin-like protein KIF2C Proteins 0.000 abstract 1
- 102100023424 Kinesin-like protein KIF2C Human genes 0.000 abstract 1
- 102000003945 NF-kappa B Human genes 0.000 abstract 1
- 108010057466 NF-kappa B Proteins 0.000 abstract 1
- 102100039306 Nucleotide pyrophosphatase Human genes 0.000 abstract 1
- 101710196623 Stimulator of interferon genes protein Proteins 0.000 abstract 1
- 102000004380 Transcription factor RelB Human genes 0.000 abstract 1
- 108090000952 Transcription factor RelB Proteins 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 238000001514 detection method Methods 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/04—Nitro compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Plant Pathology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762530661P | 2017-07-10 | 2017-07-10 | |
| PCT/US2018/041480 WO2019014246A1 (en) | 2017-07-10 | 2018-07-10 | TARGETING CHROMOSOMIC INSTABILITY AND SIGNALING OF CYTOSOLIC DNA IN AVAL FOR THE TREATMENT OF CANCER |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020000406A true MX2020000406A (es) | 2020-10-01 |
Family
ID=63036469
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020000406A MX2020000406A (es) | 2017-07-10 | 2018-07-10 | Tratamiento dirigido de la inestabilidad cromosómica y senalización del adn citosólico gen abajo para el tratamiento del cáncer. |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11821042B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3652349A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7197556B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20200037796A (cg-RX-API-DMAC7.html) |
| CN (1) | CN111295454A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2018300007A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112020000477A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3069515A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL271849A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2020000406A (cg-RX-API-DMAC7.html) |
| SG (1) | SG11202000132WA (cg-RX-API-DMAC7.html) |
| WO (1) | WO2019014246A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201901393VA (en) * | 2016-09-02 | 2019-03-28 | Univ Illinois | Kif13b-derived peptide and method of inhibiting angiogenesis |
| US11821042B2 (en) | 2017-07-10 | 2023-11-21 | Cornell University | Targeting chromosomal instability and downstream cytosolic DNA signaling for cancer treatment |
| JP7226763B2 (ja) * | 2017-08-17 | 2023-02-21 | 国立大学法人山口大学 | 癌幹細胞における薬物耐性の低減剤、癌幹細胞における転移能の抑制剤及び癌の転移性再発リスクを予測する方法 |
| US20230106899A1 (en) * | 2019-06-21 | 2023-04-06 | Ifm Due, Inc. | Methods of treating cancer |
| WO2021167478A1 (en) * | 2020-02-19 | 2021-08-26 | Ibmc - Instituto De Biologia Molecular E Celular | 4-pyrrolidin-1-yl-5-p-tolyl-thieno[2,3-d] pyrimidine for use in the treatment of aging-associated and premature aging diseases through restored chromosomal stability and inhibition of cellular senescence |
| CN112113821B (zh) * | 2020-05-28 | 2021-09-03 | 王剑 | 一种细胞病理学样本的多重染色制片方法 |
| WO2022051420A1 (en) * | 2020-09-02 | 2022-03-10 | Memorial Sloan Kettering Cancer Center | Methods and compositions for targeting cytosolic dsdna signaling in chromosomally unstable cancers |
| US20240207248A1 (en) * | 2021-04-23 | 2024-06-27 | Baruch S. Blumberg Institute | Methods, kits and compositions for reducing chromosomal instability in cancer cells |
| CN113341154B (zh) * | 2021-05-14 | 2024-11-05 | 医工瑞思(福建)工程研究中心有限公司 | 一种检测血栓或凝血相关疾病的生物标志物及其应用 |
| KR20240109977A (ko) | 2021-08-26 | 2024-07-12 | 볼라스트라 쎄라퓨틱스, 인코포레이티드 | Kif18a의 스피로 인돌린 억제제 |
| CN115354078B (zh) * | 2022-09-02 | 2023-07-07 | 中山大学附属第一医院 | 骨肉瘤检测标记物及其应用 |
| EP4488389A1 (en) * | 2023-07-05 | 2025-01-08 | Fundación del Sector Público Estatal Centro Nacional de Investigaciones Oncológicas Carlos III (F.S.P. CNIO) | Signature for the prognosis of brain metastasis relapse |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4962091A (en) | 1986-05-23 | 1990-10-09 | Syntex (U.S.A.) Inc. | Controlled release of macromolecular polypeptides |
| WO1994007529A1 (en) | 1992-09-25 | 1994-04-14 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
| US6306434B1 (en) | 1997-02-12 | 2001-10-23 | Chong Kun Dang Corp. | Pharmaceutical composition comprising cyclosporin solid-state microemulsion |
| GB201121070D0 (en) | 2011-12-07 | 2012-01-18 | Isis Innovation | composition for delivery of biotherapeutics |
| JP2016506408A (ja) * | 2012-12-19 | 2016-03-03 | ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム | 哺乳動物の環状ジヌクレオチドシグナル伝達経路の薬学的標的化 |
| EP3045917A2 (en) * | 2013-09-13 | 2016-07-20 | Sierra Jiménez, Angels | Marker for predicting metastasis of breast cancer |
| SG10201807838SA (en) * | 2014-03-11 | 2018-10-30 | Council Queensland Inst Medical Res | Determining cancer aggressiveness, prognosis and responsiveness to treatment |
| CN107106544B (zh) * | 2014-09-19 | 2021-09-24 | 纪念斯隆-凯特琳癌症中心 | 用于治疗脑转移瘤的方法 |
| WO2016176222A1 (en) * | 2015-04-30 | 2016-11-03 | University Of Washington | Cgas in systemic lupus erythematosus (sle) |
| US11821042B2 (en) | 2017-07-10 | 2023-11-21 | Cornell University | Targeting chromosomal instability and downstream cytosolic DNA signaling for cancer treatment |
-
2018
- 2018-07-10 US US16/629,512 patent/US11821042B2/en active Active
- 2018-07-10 BR BR112020000477-4A patent/BR112020000477A2/pt not_active Application Discontinuation
- 2018-07-10 SG SG11202000132WA patent/SG11202000132WA/en unknown
- 2018-07-10 KR KR1020207003861A patent/KR20200037796A/ko not_active Withdrawn
- 2018-07-10 WO PCT/US2018/041480 patent/WO2019014246A1/en not_active Ceased
- 2018-07-10 CA CA3069515A patent/CA3069515A1/en active Pending
- 2018-07-10 AU AU2018300007A patent/AU2018300007A1/en not_active Abandoned
- 2018-07-10 MX MX2020000406A patent/MX2020000406A/es unknown
- 2018-07-10 CN CN201880058523.8A patent/CN111295454A/zh active Pending
- 2018-07-10 JP JP2020500887A patent/JP7197556B2/ja active Active
- 2018-07-10 EP EP18746496.1A patent/EP3652349A1/en active Pending
-
2020
- 2020-01-06 IL IL271849A patent/IL271849A/en unknown
-
2023
- 2023-04-12 US US18/299,558 patent/US20240110246A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2018300007A1 (en) | 2020-02-27 |
| US20210130903A1 (en) | 2021-05-06 |
| US11821042B2 (en) | 2023-11-21 |
| US20240110246A1 (en) | 2024-04-04 |
| BR112020000477A2 (pt) | 2020-07-21 |
| SG11202000132WA (en) | 2020-02-27 |
| JP7197556B2 (ja) | 2022-12-27 |
| IL271849A (en) | 2020-02-27 |
| CN111295454A (zh) | 2020-06-16 |
| WO2019014246A1 (en) | 2019-01-17 |
| CA3069515A1 (en) | 2019-01-17 |
| EP3652349A1 (en) | 2020-05-20 |
| JP2020526206A (ja) | 2020-08-31 |
| KR20200037796A (ko) | 2020-04-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12020500396A1 (en) | Ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp-1) inhibitors and uses thereof | |
| BR112019024525A2 (pt) | composto, sal farmaceuticamente aceitável e formulação farmacêutica de inibidores de kras c12c | |
| CY1122038T1 (el) | Ετεροδιλειτουργικοι αναστολεις των ε-σελεκτινων και των υποδοχεων χημειοκινης cxcr4 | |
| MX2020012731A (es) | Inhibidores de kras g12c y metodos para su uso. | |
| CY1120373T1 (el) | Συνθεσεις που περιλαμβανουν βακτηριακα στελεχη | |
| PH12020550936A1 (en) | Combination drug including tlr7 agonist | |
| MX2020002502A (es) | Inhibidores de kras g12c y metodos para utilizarlos. | |
| NZ730771A (en) | Aurora a kinase inhibitor | |
| WO2019067666A8 (en) | Therapeutic methods relating to hsp90 inhibitors | |
| MX2018008346A (es) | Terapia de combinación de virus oncológico e inhibidor de punto de control. | |
| BR112015026307A2 (pt) | heterociclo bicíclicos como inibidores de fgfr | |
| MX2021001550A (es) | Inhibidores de transglutaminasa 2 (tg2). | |
| MX2009006627A (es) | Quinazolinas para la inhibicion de pdk1. | |
| SG10201808940WA (en) | Nox inhibitor and nfкb inhibitor containing methoxyflavone | |
| MY179690A (en) | Lubricant material for assisting machining process and machining method | |
| MX370662B (es) | Composiciones que comprenden nanopartículas de paclitaxel y albúmina para usarse en el tratamiento de cáncer. | |
| AU2018380132A8 (en) | Tubulin inhibitors | |
| BR112021022397A2 (pt) | Composição | |
| MX390320B (es) | Farmaco de combinacion. | |
| GB2553439A (en) | Methods for scoring chromosomal instabilities | |
| PH12020500638A1 (en) | Chromene derivatives as inhibitors of tcr-nck interaction | |
| MX2019008545A (es) | Estabilidad mejorada de composiciones que contienen inhibidor de la ureasa. | |
| ZA201808562B (en) | Phthalazine derivatives as inhibitors of parp1, parp2 and/or tubulin useful for the treatment of cancer | |
| ZA202206308B (en) | Ezetimibe and curcumin for use in cancer treatment | |
| Genaro-Mattos et al. | Correction: Antioxidant Activity of Caffeic Acid against Iron-Induced Free Radical Generation—A Chemical Approach |